In the last 20 years, several clinical trials on neoadjuvant chemotherapy and chemo-radiotherapy as a therapeutic approach for locally advanced gastric cancer have been performed. Even if more data are necessary to define the roles of these approaches, the results of preoperative treatments in the combined treatment of gastric adenocarcinoma are encouraging because this approach has led to a higher rate of curative surgical resection. Owing to the results of most recent randomized phase III studies, neoadjuvant chemotherapy for locally advanced resectable gastric cancer has satisfied the determination of level I evidence. Remaining concerns pertain to the choice of the optimal therapy regimen, strict patient selection by accurate pre-operative staging, standardization of surgical procedures, and valid criteria for response evaluation. New well-designed trials will be necessary to find the best therapeutic approach in pre-operative settings and the best way to combine old-generation chemotherapeutic drugs with new-generation molecules.

Biondi, A., Lirosi, M. C., D'ugo, D., Fico, V., Ricci, R., Santullo, F., Rizzuto, A., Cananzi, F. C. M., Persiani, R., Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives, <<WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY>>, 2015; 7 (12): 389-400. [doi:10.4251/wjgo.v7.i12.389] [http://hdl.handle.net/10807/71217]

Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives

Biondi, Alberto;Lirosi, Maria Carmen;D'Ugo, Domenico;Fico, Valeria;Ricci, Riccardo;Santullo, Francesco;Cananzi, Ferdinando Carlo Maria;Persiani, Roberto
2015

Abstract

In the last 20 years, several clinical trials on neoadjuvant chemotherapy and chemo-radiotherapy as a therapeutic approach for locally advanced gastric cancer have been performed. Even if more data are necessary to define the roles of these approaches, the results of preoperative treatments in the combined treatment of gastric adenocarcinoma are encouraging because this approach has led to a higher rate of curative surgical resection. Owing to the results of most recent randomized phase III studies, neoadjuvant chemotherapy for locally advanced resectable gastric cancer has satisfied the determination of level I evidence. Remaining concerns pertain to the choice of the optimal therapy regimen, strict patient selection by accurate pre-operative staging, standardization of surgical procedures, and valid criteria for response evaluation. New well-designed trials will be necessary to find the best therapeutic approach in pre-operative settings and the best way to combine old-generation chemotherapeutic drugs with new-generation molecules.
Inglese
Biondi, A., Lirosi, M. C., D'ugo, D., Fico, V., Ricci, R., Santullo, F., Rizzuto, A., Cananzi, F. C. M., Persiani, R., Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives, <<WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY>>, 2015; 7 (12): 389-400. [doi:10.4251/wjgo.v7.i12.389] [http://hdl.handle.net/10807/71217]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/71217
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 24
social impact